Vivesto AB · OMXSTO:VIVE
Vivesto AB — Oasmia Pharmaceutical — Q2 2020/2021 Earnings Presentation
15 slides from Vivesto AB's earnings presentation, Dec 9, 2020
Slide 1: Q2 Results (August – October 2020)
Q2 RESULTS (AUGUST – OCTOBER 2020) F.R. Martelet, M.D., CEO 9 December 2020 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Today's speakers
Today’s speakers FRANCOIS MARTELET, M.D., ROBERT MAIORANA Master’s Degree Business Acting Chief Financial Officer Chief Executive Officer 3
Slide 4: Q2 Corporate Highlights
Q2 Corporate Highlights • Sustained progress on Apealea with partner Elevar Therapeutics ‒ Agreement signed for commercialization in MENA ‒ Global Named Patient Program initiated ex-US ‒ Clear path set for regulatory submission in US with expanded clinical program (post period) ‒ Initial prescriptio
Slide 5: Q2 Financial Highlights
Q2 Financial Highlights • Cash and cash equivalents & short-term investments TSEK 329,588 (29,039) ‒ Several one-off costs during the quarter: • MSEK 3.1 fine from NASDAQ • MSEK 3.4 write down due to reduced need for premises in Uppsala • TSEK -18,114 (-14,449) employee benefit expenses relating to
Slide 6: Management and Senior Team strengthened
Management and Senior Team strengthened FRANCOIS MARTELET, M.D., FREDRIK JÄRRSTEN MBA PETER SELIN BSc ROBERT MAIORANA BSc Master’s Degree Business Chief Financial Officer Chief Business Officer Finance Manager (Current Chief Executive Officer Acting Chief Financial Officer) • …plus, TWO Senior Scien
Slide 7: Building a portfolio based on XR-17 platform technology
Building a portfolio based on XR-17™ platform technology Registration / Commercial Product Indication Pre-clinical Phase I Phase II Phase III approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer USA Paclical® (paclitaxel) Ovarian cancer EU / EEA Docetaxel Prostate cancer Global
Slide 8: The pillars of Oasmia's strategy from 2021 onwards
The 4 pillars of the Oasmia’s strategy from 2021 onwards 1 2 3 4 Execute on Apealea Partnering & clinical Clinical In / out-licensing, global partnership development with development of partnering & M&A with Elevar XR-17™ / XR-19 Docetaxel micellar in oncology Therapeutics platforms and new API(s) 8
Slide 9: Sustained progress on Apealea with Elevar Therapeutics
Sustained progress on Apealea with Elevar Therapeutics 1 • Global commercial partnering program progressing well ‒ Agreement signed with Taiba Middle East FZ LLC for Middle East and North Africa region. ‒ Global named patient program initiated with Tanner ex-US where Apealea not yet commercially ava
Slide 10: Improving and investing in our technologies
Improving and investing in our technologies 2 XR-17™ • Specialist consultancy firm hired to drive partnering XR-18 • R&D underway on next generation of XR-17™ solubilizing platform • Work initiated to further improve and differentiate platform, with the ambition to enable improved versatility and br
Slide 11: Docetaxel micellar poised for clinical development
Docetaxel micellar poised for clinical development 3 1 in 7 1.3m men will be men were newly diagnosed with diagnosed with prostate prostate cancer cancer in 20181 • Docetaxel is approved for wide range of solid malignancies and standard of care for advanced prostate cancer • Docetaxel micellar uses
Slide 12: Investment bank hired to drive partnering of animal health portfolio
Investment bank hired to drive partnering of animal health portfolio 4 Paccal Vet Doxophos Vet • A new XR-17™-based formulation of paclitaxel in • A patented formulation of doxorubicin in combination development for the treatment of mastocytoma in dogs with XR-17™ for the treatment of lymphoma, one
Slide 13: Recent progress made for each pillar of our strategy
Recent progress made for each pillar of our strategy 1 2 3 4 Execute on Apealea Partnering & clinical Clinical development In / out-licensing, global partnership with development with of Docetaxel micellar partnering & M&A in Elevar Therapeutics XR-17™ / XR-19 platforms and new API(s) oncology Comme
Slide 14: Looking ahead – multiple catalysts and investment drivers
Looking ahead – multiple catalysts and investment drivers Potential near and mid-term value drivers Investment drivers • Elevar partnering for Apealea in Europe, Asia, • Commercial-stage company with proven LatAm capabilities • SAKK docetaxel micellar Phase Ib initiation • Validated XR-17™ technolog
Slide 15: Oasmia
oasmia
Oasmia Pharmaceutical — Q2 2020/2021 Earnings Presentation on 6ix